The list and price announcement of the seventh batch of drugs that won the bid for centralized drug procurement organized by the state involved 31 treatment categories
On the 12th, under the organization and guidance of the National Medical Insurance Administration and other relevant departments, the seventh batch of centralized procurement of drugs organized by the state was opened in Nanjing.
This centralized purchase of drugs involves 31 treatment categories, including drugs for common and chronic diseases such as hypertension, diabetes, anti-infection, and digestive tract diseases, as well as drugs for major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. Strong sense of gain. Taking the first-line targeted drug lenvatinib capsules for liver cancer as an example, each capsule has dropped from an average of 108 yuan to an average of 18 yuan, and one treatment cycle can save 8,100 yuan. In the field of blood pressure lowering, it was the first time to include sustained and controlled release dosage forms. The price of nifedipine controlled-release tablets was reduced by 58%, and the price of metoprolol sustained-release tablets was reduced by 53%, which significantly reduced the drug burden of hypertensive patients. The antiviral drug oseltamivir dropped from an average of 4.5 yuan to 1 yuan per tablet. In addition, four original research drugs, including tigecycline from Pfizer in the United States, micafungin from Astellas in Japan, ebastine from Emero from Spain, and Dipatrol from Bracco Xinyi from Italy When selected, the average price is reduced by 67%. So far, the state has organized seven batches of centralized procurement with volume, and a total of 294 kinds of drugs have been successfully purchased.
Drug List and Price Details>>
(CCTV reporter Zhang Ping)
Copyright and Disclaimer
Copyright statement: All the manuscripts whose source is “Interchange, Xinhua Daily and its sub-newspapers” or whose telegram is “Xinhua Newspaper Net” are the exclusive copyright of Xinhua Newspaper Net, and may not be reproduced or mirrored without permission; The source must be indicated as “Xinhua Newspaper Net”, and the telephone number of “Xinhua Newspaper Net” must be retained.
Disclaimer: The manuscripts reproduced on this site only represent the author’s personal views and have nothing to do with Xinhua Newspapers.com. Its originality and the text and content stated in the text have not been verified by this site, and this site does not make any guarantee or commitment to the authenticity, completeness and timeliness of this text and all or part of its content and text. Readers are only for reference, and please Verify the relevant content yourself.